Tre mesi di azitromicina in aggiunta alla terapia standard migliorano il controllo dell’asma nei casi più difficili

Abstract

Three months of azithromycin in addition to standard therapy improves asthma control in the most difficult cases This Indian study carried out during the pandemic years, with some limitations related to the difficulty of reevaluating patients because of the restrictions in place, shows us that in uncontrolled asthma, the addition of azithromycin (10 mg/Kg 3 times a week for 3 months) leads to an improvement in disease control in children aged 5 to 15 years in whom adherence to basic therapy (with inhaled corticosteroids and/or long-acting ß-agonists) has already been reinforced and deemed adequate. This is a relatively simple and low-cost therapy that is feasible even in resource-limited countries. A total of 120 patients (60 per arm) were enrolled; treatment efficacy was assessed by questionnaires (ACT/CACT) showing that in treated patients there is a statistically significant improvement in symptoms and a marked increase in patients with well-controlled asthma according to GINA guidelines, which is not the case in the control arm taking baseline therapy alone. No adverse events were observed and no resistant germs appeared in the treated group.